Could a lower HIV drug dose work just as well?
NCT ID NCT02384967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a lower daily dose of the HIV drug darunavir (400 mg instead of 800 mg) can keep the virus suppressed in people whose HIV is already well-controlled. The trial involved 100 adults with HIV who had undetectable viral loads for at least a year. The goal was to see if the reduced dose could maintain viral suppression for 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darunavir (a lower dose of 400 mg per day instead of the usual 800 mg)
What this could lead to
If successful, this could allow some people with HIV to take a lower dose of darunavir while still keeping the virus under control, potentially reducing side effects and costs.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 100 participants. It is not yet proven that the lower dose works as well as the standard dose, and there is a risk of the virus becoming detectable again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Saint Louis
Paris, 75010, France